<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20083">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02845453</url>
  </required_header>
  <id_info>
    <org_study_id>Quetiapine Protocol</org_study_id>
    <nct_id>NCT02845453</nct_id>
  </id_info>
  <brief_title>Treatment With Quetiapine for Youth With Substance Use Disorders and Bipolar Disorder</brief_title>
  <official_title>A Randomized Controlled Trial of Quetiapine for the Treatment of Youth With Co-occurring Substance Use Disorders (SUDs) and Bipolar Disorder (BD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether quetiapine is effective in the treatment
      of youth with co-occurring substance use disorders and bipolar disorder.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Timeline Followback in Self-Reported Substance Use for Primary Substance of Use</measure>
    <time_frame>8 weeks</time_frame>
    <description>The timeline followback of substance use will be used to quantify self-reported alcohol and drug use.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in Young Mania Rating Scale (YMRS) Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>The YMRS consists of 11 items rated on a scale from 0 (symptoms not present) to 4 (symptoms extremely severe). It is used to assess manic symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Number of Toxicology Specimens Negative</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>The number of toxicology specimens for primary substance of use will be measured at baseline and endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Weiss Craving Scale Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Weiss Craving Scale consists of 3 items rated on a scale from 0 (no desire/likelihood of use) to 9 (strong desire/likelihood of use). It is used to assess cravings for a drug of choice.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Beck Depression Inventory (BDI-II) Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>The BDI-II consists of 21 items rated on a scale from 0 (symptoms not present) to 3 (symptoms extremely severe). It assesses depressive symptomatology over 2 weeks prior to administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Substance Use Disorders</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Quetiapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quetiapine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <arm_group_label>Quetiapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female age 15 to 24

          -  Meet DSM-5 criteria for a substance use disorder

          -  Substance use ≥ 14 days of past 28 days (i.e. use ≥ 50% of days in the past 28 days)

          -  If subject in restricted setting/care (e.g. detox or residential treatment) for ≤ 2
             weeks, then use ≥ 50% of days while outside of restricted setting (e.g. 7 days of
             substance use out of 14 days in unrestricted setting)

          -  Meet DSM-5 criteria for bipolar disorder

          -  YMRS ≥ 20

          -  Stable to be treated in outpatient level of care

        Exclusion Criteria:

          -  Current opioid or methamphetamine use disorder

          -  Pregnant or breastfeeding

          -  Placement in a restricted setting (e.g. detox or residential treatment) for ≥ 2 weeks
             out of past 28 days

          -  Unwilling or unable to use effective birth control

          -  Unwilling or unable to sign release of information for the treatment program
             providing behavioral treatment

          -  For participants &gt;17 years—unable or unwilling to identify emergency contact

          -  Medical or psychiatric condition likely to make participation unsafe as judged by the
             clinical investigator

          -  History of QTc&gt;450 or arrhythmia, family history of malignant arrhythmia, for sudden
             death

          -  AST or ALT greater than three times normal

          -  BMI ≥ 95th percentile

          -  Poor command of the English language

          -  Current treatment with quetiapine, or an allergy to quetiapine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Yule, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicholas Carrellas</last_name>
    <phone>617-724-5226</phone>
    <email>ncarrellas@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexa Pulli</last_name>
    <phone>617-726-4651</phone>
    <email>apulli@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Carrellas, BA</last_name>
      <phone>617-724-5226</phone>
      <email>ncarrellas@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Alexa Pulli, BS</last_name>
      <phone>617-726-4651</phone>
      <email>apulli@partners.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 8, 2017</lastchanged_date>
  <firstreceived_date>July 14, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Amy Yule</investigator_full_name>
    <investigator_title>Assistant in Psychiatry, Massachusetts General Hospital, Instructor at Harvard Medical School, Medical Director of the Addiction and Recovery Management Service</investigator_title>
  </responsible_party>
  <keyword>youth</keyword>
  <keyword>adolescent</keyword>
  <keyword>young adult</keyword>
  <keyword>substance use disorder</keyword>
  <keyword>bipolar disorder</keyword>
  <keyword>quetiapine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
